AVBP

Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell lines and NSCLC animal modelsSuperior anti-tumor activity of ARR-002 in ovarian cancer models compared to single-target or bivalent approaches with favorable tolerability underscores best-in-disease ADC potential NEWTOWN SQUARE, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced two poster presentations at the 2026 American Association for Cancer Research (AACR) A

Aarvik Therapeutics, an innovative, ADC-focused biotechnology company dedicated to engineering precision medicines for cancer therapy, is pleased to announce that it will present two posters and a minisymposium talk at the AACR Annual Meeting 2026. These presentations display the breadth of Aarvik's capabilities in the ADC space. The AACR Annual Meeting will take place from April 17-22, 2026, in San Diego, California. Aarvik, along with collaborator ArriVent BioPharma, Inc. (NASDAQ:AVBP), will present a poster titled "AV-P138-ADC (ARR-002), a novel MUC16/NaPi2b dual-target tetravalent ADC, for the treatment of ovarian and endometrial cancers" (Poster Number 2660). AV-P138-ADC, also known

8-K - ArriVent BioPharma, Inc. (0001868279) (Filer)

BTIG Research resumed coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $42.00

S-8 - ArriVent BioPharma, Inc. (0001868279) (Filer)

10-K - ArriVent BioPharma, Inc. (0001868279) (Filer)

8-K - ArriVent BioPharma, Inc. (0001868279) (Filer)

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 first-line PACC mutant NSCLC study for firmonertinib enrollment underwayADC pipeline advancing with first ADC program, ARR-217, in Phase 1 clinical development Cash and investments of $312.8 million as of December 31, 2025 expected to fund operations into 3Q 2027 NEWTOWN SQUARE, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the year ended

SCHEDULE 13G/A - ArriVent BioPharma, Inc. (0001868279) (Subject)

SCHEDULE 13G/A - ArriVent BioPharma, Inc. (0001868279) (Subject)

The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 5, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – The FDA isn't just approving drugs; they are completely reshaping the landscape. In 2025 alone, the agency issued over 50 oncology approvals[1], but the real story is the aggressive pivot toward targeted therapies for high-unmet-need solid tumors. That momentum has accelerated in 2026 with a sudden flurry of expedited designations[2] for RAS inhibitors and rare malignancies. This regulatory velocity creates a clear validation framework, positioning Oncolytics Biotech Inc. (NASDAQ:ONCY), Relay Therapeutics (NASDAQ:RLAY), MAIA Biotechnology (NYSE-A: MAIA), Zai Lab (NASDAQ:

4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

SCHEDULE 13G/A - ArriVent BioPharma, Inc. (0001868279) (Subject)

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Jan. 12, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – The oncology landscape is entering a high-velocity regulatory phase as genomics in cancer care expands toward a projected $69.16 billion by 2032[1]. This massive growth is driven by the systematic integration of genotype-directed treatment pathways into standard medical practice. The precision medicine market is now on a trajectory to expand from $138.67 billion in 2026 to over $537.17 billion by 2035[2]. This strategic pivot toward registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), CG Oncology (NASDAQ:CGON), Ze

Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to support potential accelerated and full regulatory approvals NEWTOWN SQUARE, Pa., Dec. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that the first patient has been dosed in the global pivotal Phase 3 ALPACCA study evaluating firmonertinib monotherapy for first-line treatment of EGFR PACC mutant non-small cell lung cance

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Gastrointestinal cancers that once resisted checkpoint inhibitors are finally responding to novel combination strategies[1], with the FDA fast-tracking multiple targeted therapies designed to transform immunologically cold tumors into treatment-responsive hot targets[2]. This pivotal shift positions Oncolytics Biotech Inc. (NASDAQ:ONCY), AIM ImmunoTech (NYSE-American: AIM), ArriVent BioPharma, Inc. (NASDAQ:AVBP), Merus N.V. (NASDAQ:MRUS), and Halozyme Therapeutics, Inc. (NASDAQ:HALO) as potential leaders in the battle against stolid tumors, including gastrointestinal ca

BTIG Research initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $45.00

Truist initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $43.00

SCHEDULE 13G/A - ArriVent BioPharma, Inc. (0001868279) (Subject)